News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
57,686 Results
Type
Article (6308)
Company Profile (13)
Press Release (51365)
Section
Business (14767)
Career Advice (50)
Deals (2261)
Drug Delivery (11)
Drug Development (12075)
Employer Resources (13)
FDA (1919)
Job Trends (2244)
News (30481)
Policy (5019)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
2026 Genetown Elite (1)
Academia (362)
Adcomms (3)
Allergies (7)
Alliances (4993)
ALS (2)
Alzheimer's disease (121)
Antibody-drug conjugate (ADC) (6)
Approvals (1946)
Artificial intelligence (13)
Autoimmune disease (3)
Automation (1)
Bankruptcy (28)
Best Places to Work (2097)
BIOSECURE Act (2)
Biosimilars (10)
Biotechnology (8)
Bladder cancer (9)
Brain cancer (2)
Breast cancer (19)
Cancer (194)
Cardiovascular disease (5)
Career advice (47)
CAR-T (21)
Cell therapy (49)
Cervical cancer (5)
Clinical research (8538)
Collaboration (78)
Compensation (8)
Complete response letters (1)
COVID-19 (2035)
CRISPR (3)
C-suite (24)
Cystic fibrosis (9)
Data (219)
Depression (1)
Diabetes (9)
Diagnostics (371)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (10)
Drug pricing (6)
Drug shortages (2)
Duchenne muscular dystrophy (4)
Earnings (4745)
Editorial (9)
Employer branding (1)
Employer resources (12)
Events (6755)
Executive appointments (43)
FDA (2093)
Featured Employer (3)
Frontotemporal dementia (1)
Funding (59)
Gene editing (11)
Generative AI (2)
Gene therapy (28)
GLP-1 (70)
Government (1812)
Grass and pollen (1)
Guidances (5)
Healthcare (1725)
Immunology and inflammation (14)
Indications (2)
Infectious disease (2133)
Inflammatory bowel disease (17)
Inflation Reduction Act (1)
Influenza (41)
Intellectual property (7)
Interviews (4)
IPO (998)
IRA (5)
Job creations (288)
Job search strategy (47)
Labor market (1)
Layoffs (68)
Legal (481)
Liver cancer (2)
Lung cancer (14)
Lymphoma (19)
Management (7)
Manufacturing (44)
MASH (1)
Medical device (364)
Medtech (364)
Mergers & acquisitions (1295)
Metabolic disorders (29)
Multiple sclerosis (15)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (152)
NextGen: Class of 2025 (337)
Non-profit (332)
Northern California (135)
Now hiring (4)
Obesity (15)
Opinion (29)
Ovarian cancer (17)
Pain (3)
Pancreatic cancer (5)
Parkinson's disease (6)
Partnered (2)
Patents (24)
Patient recruitment (1)
Peanut (6)
People (4291)
Pharmaceutical (5)
Phase I (3037)
Phase II (3549)
Phase III (3220)
Pipeline (106)
Podcasts (15)
Policy (31)
Postmarket research (385)
Preclinical (1181)
Press Release (19)
Prostate cancer (6)
Psychedelics (4)
Radiopharmaceuticals (13)
Rare diseases (34)
Real estate (485)
Recruiting (5)
Regulatory (3228)
Reports (11)
Research institute (381)
Resumes & cover letters (2)
RNA editing (2)
RSV (46)
Schizophrenia (1)
Series A (6)
Series B (4)
Service/supplier (1)
Sickle cell disease (5)
Southern California (129)
Spinal muscular atrophy (2)
Sponsored (4)
Startups (271)
Supply chain (10)
The Weekly (14)
United States (1769)
Vaccines (762)
Venture capitalists (3)
Webinars (1)
Weight loss (16)
Date
Today (21)
Last 7 days (67)
Last 30 days (250)
Last 365 days (3068)
2025 (681)
2024 (3169)
2023 (3757)
2022 (6878)
2021 (7817)
2020 (6285)
2019 (2805)
2018 (2146)
2017 (2139)
2016 (2119)
2015 (2570)
2014 (2004)
2013 (1630)
2012 (1817)
2011 (1957)
2010 (1816)
Location
Africa (161)
Alabama (17)
Alaska (1)
Arizona (3)
Asia (3949)
Australia (621)
California (319)
Canada (140)
China (35)
Colorado (11)
Connecticut (20)
Delaware (12)
Europe (9335)
Florida (42)
Georgia (40)
Idaho (1)
Illinois (16)
India (5)
Indiana (24)
Japan (19)
Kansas (8)
Kentucky (2)
Maine (1)
Maryland (277)
Massachusetts (241)
Michigan (8)
Minnesota (7)
Missouri (10)
Montana (8)
Nebraska (2)
Nevada (1)
New Hampshire (1)
New Jersey (306)
New Mexico (3)
New York (146)
North Carolina (50)
North Dakota (6)
Northern California (135)
Ohio (9)
Pennsylvania (129)
Puerto Rico (1)
Rhode Island (5)
South America (97)
South Carolina (1)
Southern California (129)
Tennessee (3)
Texas (30)
Utah (5)
Virginia (8)
Washington D.C. (3)
Washington State (39)
Wisconsin (1)
57,686 Results for "vbi vaccines".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
VBI Vaccines Reports First Quarter 2024 Financial Results
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.
May 15, 2024
·
16 min read
Drug Development
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.
May 29, 2024
·
11 min read
Genetown
VBI Vaccines Announces Results of Annual General Meeting - June 25, 2024
VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the voting results from its annual general meeting of shareholders held on June 25, 2024.
June 25, 2024
·
2 min read
Drug Development
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
VBI Vaccines Inc. today announced that David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will present early tumor response data from the ongoing Phase 2b study of VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (rGBM) at the World Vaccine Congress Washington at 1:10pm ET on April 3, 2024.
April 3, 2024
·
9 min read
Drug Development
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 22, 2024
·
6 min read
Business
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform.
April 2, 2024
·
6 min read
Business
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
April 16, 2024
·
18 min read
Genetown
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares of VBI at an offering price of $0.88 per common share, in a registered direct offering priced at-the-market under the Nasdaq rules.
April 9, 2024
·
6 min read
Drug Development
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 1 clinical study of its multivalent pan-coronavirus vaccine candidate, VBI-2901, which expresses the ancestral COVID-19, SARS, and MERS spike antigens.
September 27, 2023
·
7 min read
Drug Development
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
VBI Vaccines Inc. today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).
September 7, 2023
·
8 min read
1 of 5,769
Next